Ductal prostate cancer staging: Role of PSMA PET/CT
https://doi.org/10.4081/aiua.2024.12132
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Introduction: To evaluate the accuracy of PSMA PET/CT in the diagnosis and clinical staging of prostatic ductal adenocarcinoma (DAC).
Materials and methods: Two Caucasian men 58 and 62 years old were admitted to our Department for dysuria: the patients had not familiarity for prostate cancer (PCa), PSA values were 5.6 and 2.8 ng/ml, digital rectal examination was positive, multiparametric magnetic resonance image (mpMRI) showed for both the presence of an index lesion PIRADS score 5. The patients underwent extended transperineal prostate biopsy combined with four mpMRI/TRUS fusion biopsy under sedation and antibiotic prophylaxis; biopsy histology demonstrated the presence of a mixed PCa characterized by DAC and acinar PCa (Grade Group 4/Gleason score 8). The patients underwent clinical staging performing lung and abdominal CT, bone scan and fluoride 18 (18F) PSMA PET/CT.
Results: Conventional imaging was negative for distant metastases; 18F-PSMA PET/CT showed in both patients an intraprostatic lesion characterized by a standardized uptake value (SUVmax) equal to 4.6 and 4.9 in the absence of distant lesions suspicious for metastases. Following multidisciplinary evaluation, the patients underwent radical prostatectomy plus extended pelvic lymphadenectomy. Definitive specimen showed the presence in both cases of a mixed pT3bN1 PCa (ductal plus acinar pattern Grade Group 4) with positive surgical margins, neuronal invasion, and nodes metastases (5/20 and 6/24, respectively). Post-operative PSA in the two patients was 0.8 and 0.3 ng/ml, therefore patients underwent adjuvant therapy.
Conclusions: Conventional imaging and PSMA PET/CT could result inadequate in clinical staging of DAC, the use of more imaging data (i.e. mpMRI and/or F-18 FDG) could improve overall accuracy.
Kawada T, Yanagisawa T, Rajwa P, et al. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2022; 5:390-400 DOI: https://doi.org/10.1016/j.euo.2022.04.006
Combes AD, Palma CA, Calopedos R. PSMA PET-CT in the diagnosis and staging of prostate cancer. Diagnostics 2022; 12:2594 DOI: https://doi.org/10.3390/diagnostics12112594
Pepe P, Pennisi M. Targeted Biopsy in Men High Risk for Prostate Cancer: 68Ga-PSMA PET/CT Versus mpMRI. Clin Genitourin Cancer. 2023; 21:639-642. DOI: https://doi.org/10.1016/j.clgc.2023.06.007
Pepe P, Pepe L, Tamburo M, et al. Targeted prostate biopsy: 68Ga- PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer. Arch Ital Urol Androl 2022; 94:274-277. DOI: https://doi.org/10.4081/aiua.2022.3.274
Pepe P, Pennisi M. Should 68Ga-PSMA PET/CT replace CT and bone scan in clinical staging of high-risk prostate cancer? Anticancer Res 2022; 42:1495-1498. DOI: https://doi.org/10.21873/anticanres.15621
Hofman MS, Lawrentschuk N, Francis RJ, et al. proPSMA StudyGroup Collaborators: Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395:1208-1216. DOI: https://doi.org/10.1016/S0140-6736(20)30314-7
Zhao Q, Dong A, Bai Y, Zuo C. Prostate-Specific Membrane Antigen Uptake Heterogeneity in Mixed Ductal Acinar Adenocarcinoma of the Prostate. Clin Nucl Med 2023; 48:750-752 DOI: https://doi.org/10.1097/RLU.0000000000004742
Qiu S, Dong A, Zhu Y, Zuo C. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate. Clin Nucl Med 2022; 47:836-838 DOI: https://doi.org/10.1097/RLU.0000000000004230
Alabed YZ Ductal Variant of Prostate Cancer: Serial Imaging With 18F-PSMA PET/CT. Clin Nucl Med 2021; 46:e551-e552. DOI: https://doi.org/10.1097/RLU.0000000000003799
Salemi M, Pettinato A, Fraggetta F, et al. Expression of miR-132 and miR-212 in prostate cancer and metastatic lymph node: Case report and revision of the literature. Arch Ital Urol Androl 2020; 92:209-210. DOI: https://doi.org/10.4081/aiua.2020.3.209
Guner LA, Unal K, Beylergil V, et al. Enhancing PSMA PET/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma. Ann Nucl Med 2023; 37: 618-628. DOI: https://doi.org/10.1007/s12149-023-01864-7
Pepe P, Pepe L, Cosentino S, et al. Detection Rate of 68Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer. Anticancer Res 2022; 42:3011-3015. DOI: https://doi.org/10.21873/anticanres.15785
Pepe P, Pennisi M. Morbidity following transperineal prostate biopsy: Our experience in 8.500 men. Arch Ital Urol Androl 2022; 94:155-159. DOI: https://doi.org/10.4081/aiua.2022.2.155
Divatia MK, Ro JY: Intraductal Carcinoma of the Prostate Gland: Recent Advances. Yonsei Med J 2016; 57:1054-62. DOI: https://doi.org/10.3349/ymj.2016.57.5.1054
Kench JG, Amin MB, Berney DM. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology 2022; 81:447-58. DOI: https://doi.org/10.1111/his.14711
Kench JG, Amin MB, Berney DM, et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology 2022; 81:447-458. DOI: https://doi.org/10.1111/his.14711
Ranasinghe W, Shapiro DD, Hwang H, et al. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol 2021; 79:298-306. DOI: https://doi.org/10.1016/j.eururo.2020.11.015
Pepe P, Garufi A, Priolo GD, et al. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. J Urol 2018; 200:774-778. DOI: https://doi.org/10.1016/j.juro.2018.04.061
Pepe P, Pepe L, Tamburo M, et al. 68Ga-PSMA PET/CT and Prostate Cancer Diagnosis: Which SUVmax Value? In Vivo 2023;37:1318-1322. DOI: https://doi.org/10.21873/invivo.13211
Pahouja G, Patel HD, Desai S, et al. The rising incidence of ductal adenocarcinoma and intraductal carcinoma of the prostate: Diagnostic accuracy of biopsy, MRI-visibility, and outcomes. Urol Oncol. 2023; 41:48.e11-48.e18. DOI: https://doi.org/10.1016/j.urolonc.2022.09.025
Zhao Q, Dong A, Bai Y, Zuo C. Prostate-Specific Membrane Antigen Uptake Heterogeneity in Mixed Ductal Acinar Adenocarcinoma of the Prostate. Clin Nucl Med 2023; 48:750-752. DOI: https://doi.org/10.1097/RLU.0000000000004742
McEwan LM, Wong D, Yaxley J. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative. J Med Imaging Radiat Oncol 2017; 61:503-505. DOI: https://doi.org/10.1111/1754-9485.12605
Qiu S, Dong A, Zhu Y, Zuo C. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate. Clin Nucl Med 2022; 47:836-838. DOI: https://doi.org/10.1097/RLU.0000000000004230
McGeorge S, Kwok M, Jiang A, et al. Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. Adv Urol. 202; 2021:1544208. DOI: https://doi.org/10.1155/2021/1544208
McEwan LM, Wong D, Yaxley J. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative. J Med Imaging Radiat Oncol. 2017; 61:503-505. DOI: https://doi.org/10.1111/1754-9485.12605
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
